The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
The consideration includes Rs. 115 crore (on the date of signing) of cash and cash equivalents in the acquired business indicating an Enterprise Value of Rs. 1,885 crore
Transformation to pure-play Innovative Medicines company nears completion
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
Dolomite Bio scientist demonstrating pipetting into the Nadia Go
Quinten Health will announce in the coming months strategic partnerships with big pharma companies and data owners to launch the first disease modeling platforms.
_256_384.jpg){kind=logo}
Veda Corporate Advisors was the exclusive financial advisor to SHPL and its shareholders.
The capital expansion program commenced in June 2022 and is expected to complete in 2024
The Board also decided that Auro Vaccines will explore the possibilities of offering contract manufacturing to global vaccine developers
The MOU provides for assistance in the form of efficient working Capital Management, development and commercialisation of new products, logistic supply chain management support etc.
Subscribe To Our Newsletter & Stay Updated
